Eli Lilly and Company (LLY) 83.32 $LLY
Pfizer (PFE) Tops on Q2 Earnings, Revenues, Maintains View
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 8:08AM CDT
Pfizer (PFE) surpassed earnings and revenue estimates again in the second quarter.
JNJ: 124.85 (-0.55), PFE: 36.39 (-0.92), LLY: 83.32 (+0.14), BMY: 75.05 (-1.14)
Merrimack (MACK): Can the Stock Surprise in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:38PM CDT
Merrimack (MACK) is scheduled to report second-quarter 2016 results on Aug 4.
MACK: 5.72 (-0.10), IRWD: 13.83 (-0.11), LLY: 83.32 (+0.14), EXEL: 9.15 (-0.12)
Top 7 Research Reports for July 29, 2016
Sheraz Mian - Zacks Investment Research - Fri Jul 29, 12:44PM CDT
Top 7 Research Reports for July 29, 2016
MDLZ: 43.03 (-0.45), JPM: 63.65 (-0.15), TMO: 156.44 (-3.12), AMGN: 174.15 (-0.01), LLY: 83.32 (+0.14), TM: 109.97 (-1.26), ORCL: 40.71 (-0.44)
AbbVie (ABBV) Beats on 2Q Earnings, Revenues, Ups View
Arpita Dutt - Zacks Investment Research - Fri Jul 29, 9:44AM CDT
AbbVie (ABBV) raised its 2016 outlook following its Q2 earnings and revenue beat.
JNJ: 124.85 (-0.55), ABBV: 66.78 (-0.16), LLY: 83.32 (+0.14), BMY: 75.05 (-1.14)
Merck (MRK) Updates Outlook Following Q2 Earnings Beat
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 9:14AM CDT
Merck (MRK) surpassed Q2 earnings expectations by a penny while revenues were in-line with estimates.
JNJ: 124.85 (-0.55), MRK: 58.33 (-0.33), LLY: 83.32 (+0.14), BMY: 75.05 (-1.14)
Business Highlights
By The Associated Press - AP - Wed Jul 27, 5:34PM CDT
___
WFM: 30.16 (-0.25), LLY: 83.32 (+0.14), CMCSK: 58.00 (-1.69), CMCSA: 66.90 (-0.64)
New Studies Suggest Relationship between Tau Pathology and Progression of Alzheimer's Disease
PR Newswire - Wed Jul 27, 3:15PM CDT
Eli Lilly and Company (NYSE: LLY) today announced results from two distinct analyses of a phase 2 study using the tau imaging agent flortaucipir ([18F] AV-1451) that evaluated the relationship between tau tangles and the progression of Alzheimer's disease. The first analysis, "Evolution of [18F] AV-1451 PET Tau Signal: Interim Analysis of an 18 Month Phase 2 Study," suggested the presence of tau tangles increased significantly over an 18-month period, consistent with ongoing cognitive decline in beta-amyloid positive patients. Further, patients with more tau at baseline accumulated tau at a faster rate, indicating the development of Alzheimer's disease accelerates as it progresses.1 The second analysis, "The Relationship of [18F] AV-1451 PET Tau Images to Changes in Cognition over Time," suggested a correlation between the location of tau in the brain and progression of cognitive decline in beta-amyloid positive patients.2 These findings were presented today at the Alzheimer's Association International Conference® 2016 (AAIC® 2016) in Toronto, Canada.
LLY: 83.32 (+0.14)
SmarTrend Watching for Potential Pullback in Shares of Eli Lilly After 1.15% Gain
Comtex SmarTrend(R) - Wed Jul 27, 1:56PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $82.15 to a high of $83.43. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $83.35 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LLY: 83.32 (+0.14)
Eli Lilly Set to Possibly Pullback After Yesterday's Rally of 1.15%
Comtex SmarTrend(R) - Wed Jul 27, 1:54PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $82.15 to a high of $83.43. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $83.35 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LLY: 83.32 (+0.14)
A Waltz with Taltz - Dermatologists Report Early Adoption of Ixekizumab in Psoriasis
PR Newswire - Wed Jul 27, 9:28AM CDT
At approximately six weeks after launch of Eli Lilly's Taltz, one-third of surveyed dermatologists (n=99) report trialling the latest biologic. RealTime Dynamix(TM): Psoriasis is an independent report issued on a quarterly basis that provides highly granular brand insights on the psoriasis market.
LLY: 83.32 (+0.14)
Long-time Lilly CEO Lechleiter to retire in December
By TOM MURPHY - AP - Wed Jul 27, 7:43AM CDT
Eli Lilly Chairman and CEO John C. Lechleiter will retire in December after leading the drugmaker through a challenging period in which it lost U.S. patent protection for several top-selling products.
LLY: 83.32 (+0.14)
John C. Lechleiter to Retire as Lilly CEO; Board Elects David A. Ricks as Successor
PR Newswire - Wed Jul 27, 5:45AM CDT
Eli Lilly and Company (NYSE: LLY) today announced that John C. Lechleiter, Ph.D., chairman, president and chief executive officer, will retire as president and CEO and from the company effective December 31, 2016. Lechleiter will continue on Lilly's board of directors until May 31, 2017, serving as non-executive chairman, at which time he will leave the board. Lilly's board of directors unanimously elected David A. Ricks, currently senior vice president and president, Lilly Bio-Medicines, to assume the role of president and chief executive officer and to join the board on January 1, 2017, and to become chairman of the board on June 1, 2017.
LLY: 83.32 (+0.14)
Biogen (BIIB) Q2 Earnings: Will the Stock Disappoint?
Arpita Dutt - Zacks Investment Research - Fri Jul 15, 8:17AM CDT
Will Tecfidera scrips and sales recover enough to boost Biogen's (BIIB) performance in the second quarter?
BIIB: 330.11 (+28.28), GILD: 79.57 (-0.89), LLY: 83.32 (+0.14), NVS: 82.96 (-0.11)
J&J (JNJ) May Beat Q2 Earnings: Will the Stock Gain?
Arpita Dutt - Zacks Investment Research - Fri Jul 15, 7:52AM CDT
J&J (JNJ) has a pretty good track record and could beat estimates in the second quarter given the Zacks Rank #2 and +1.80% ESP.
JNJ: 124.85 (-0.55), GILD: 79.57 (-0.89), LLY: 83.32 (+0.14), NVS: 82.96 (-0.11)
Eli Lilly, Boehringer Collaborate for Metastatic Breast Cancer
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 9:25AM CDT
Eli Lilly (LLY) inked a clinical trial collaboration with Boehringer for the evaluation of abemaciclib-BI 836845 combination for metastatic breast cancer.
ABT: 45.07 (-0.22), JNJ: 124.85 (-0.55), INVA: 12.84 (-0.20), LLY: 83.32 (+0.14)
Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer
PR Newswire - Wed Jul 13, 7:00AM CDT
Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced a new collaboration on a Phase 1b study that will evaluate the safety and tolerability of abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor, in combination with BI 836845, Boehringer Ingelheim's insulin-like growth factor (IGF)-1/IGF-2 ligand neutralizing antibody, in patients diagnosed with HR+, HER2- mBC. Based on the Phase 1b trial results, the collaboration has the potential to expand to Phase 2 trials in patients with HR+, HER2- mBC and other solid tumors. Enrollment is scheduled to begin in late 2016, and Boehringer Ingelheim will be the sponsor of the study program.
LLY: 83.32 (+0.14)
Testosterone Replacement Therapy (TRT) Market to Face Lean Patch until 2024 as it Inches Close to Patent Cliff, Says TMR
PR Newswire Europe - Tue Jul 12, 11:31AM CDT
ALBANY, New York, July 12, 2016 /PRNewswire/ --
AGN: 250.75 (-4.11), ENDP: 17.11 (+0.23), LLY: 83.32 (+0.14), ABBV: 66.78 (-0.16)
2016 INVESTIndiana Equity Conference Announces Corporate Presentation Lineup
BusinessWire - Tue Jul 12, 10:00AM CDT
INVESTIndiana, an equity conference that highlights the performance of Indiana public companies, today announced a presentation lineup that features Indiana's top health sciences companies as well as leaders in the banking, energy, high-tech and manufacturing sectors.
ESCA: 10.72 (+0.01), ININ: 56.96 (+5.31), ZBH: 130.59 (-0.47), GABC: 34.26 (-0.03), KBAL: 11.58 (+0.10), HBNC: 27.10 (-0.19), LLY: 83.32 (+0.14), LKFN: 50.80 (-0.43), SRCE: 33.56 (-0.15), ONB: 13.15 (+0.10), ECYT: 3.05 (-0.13), NI: 25.94 (+0.13), INBK: 22.21 (-0.67), BASI: 1.39 (+0.21), MFSF: 28.16 (-0.17)
Technical Report on Drug Manufacturers - Major Stocks - Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
PR Newswire - Mon Jul 11, 6:55AM CDT
On Friday, July 08, 2016, the NASDAQ Composite ended the trading session at 4,956.76, up 1.64%; the Dow Jones Industrial Average advanced 1.40%, to finish at 18,146.74; and the S&P 500 closed at 2,129.90, up 1.53%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Bristol-Myers Squibb Company (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Company (NYSE: LLY), and GlaxoSmithKline PLC (NYSE: GSK). Learn more about these stocks by accessing their free notes at:
AZN: 34.21 (+0.37), LLY: 83.32 (+0.14), GSK: 45.49 (+0.24), BMY: 75.05 (-1.14)
Pfizer (PFE) Tops on Q2 Earnings, Revenues, Maintains View
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 8:08AM CDT
Pfizer (PFE) surpassed earnings and revenue estimates again in the second quarter.
JNJ: 124.85 (-0.55), PFE: 36.39 (-0.92), LLY: 83.32 (+0.14), BMY: 75.05 (-1.14)
Merrimack (MACK): Can the Stock Surprise in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 5:38PM CDT
Merrimack (MACK) is scheduled to report second-quarter 2016 results on Aug 4.
MACK: 5.72 (-0.10), IRWD: 13.83 (-0.11), LLY: 83.32 (+0.14), EXEL: 9.15 (-0.12)
Top 7 Research Reports for July 29, 2016
Sheraz Mian - Zacks Investment Research - Fri Jul 29, 12:44PM CDT
Top 7 Research Reports for July 29, 2016
MDLZ: 43.03 (-0.45), JPM: 63.65 (-0.15), TMO: 156.44 (-3.12), AMGN: 174.15 (-0.01), LLY: 83.32 (+0.14), TM: 109.97 (-1.26), ORCL: 40.71 (-0.44)
AbbVie (ABBV) Beats on 2Q Earnings, Revenues, Ups View
Arpita Dutt - Zacks Investment Research - Fri Jul 29, 9:44AM CDT
AbbVie (ABBV) raised its 2016 outlook following its Q2 earnings and revenue beat.
JNJ: 124.85 (-0.55), ABBV: 66.78 (-0.16), LLY: 83.32 (+0.14), BMY: 75.05 (-1.14)
Merck (MRK) Updates Outlook Following Q2 Earnings Beat
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 9:14AM CDT
Merck (MRK) surpassed Q2 earnings expectations by a penny while revenues were in-line with estimates.
JNJ: 124.85 (-0.55), MRK: 58.33 (-0.33), LLY: 83.32 (+0.14), BMY: 75.05 (-1.14)
Business Highlights
By The Associated Press - AP - Wed Jul 27, 5:34PM CDT
___
WFM: 30.16 (-0.25), LLY: 83.32 (+0.14), CMCSK: 58.00 (-1.69), CMCSA: 66.90 (-0.64)
New Studies Suggest Relationship between Tau Pathology and Progression of Alzheimer's Disease
PR Newswire - Wed Jul 27, 3:15PM CDT
Eli Lilly and Company (NYSE: LLY) today announced results from two distinct analyses of a phase 2 study using the tau imaging agent flortaucipir ([18F] AV-1451) that evaluated the relationship between tau tangles and the progression of Alzheimer's disease. The first analysis, "Evolution of [18F] AV-1451 PET Tau Signal: Interim Analysis of an 18 Month Phase 2 Study," suggested the presence of tau tangles increased significantly over an 18-month period, consistent with ongoing cognitive decline in beta-amyloid positive patients. Further, patients with more tau at baseline accumulated tau at a faster rate, indicating the development of Alzheimer's disease accelerates as it progresses.1 The second analysis, "The Relationship of [18F] AV-1451 PET Tau Images to Changes in Cognition over Time," suggested a correlation between the location of tau in the brain and progression of cognitive decline in beta-amyloid positive patients.2 These findings were presented today at the Alzheimer's Association International Conference® 2016 (AAIC® 2016) in Toronto, Canada.
LLY: 83.32 (+0.14)
SmarTrend Watching for Potential Pullback in Shares of Eli Lilly After 1.15% Gain
Comtex SmarTrend(R) - Wed Jul 27, 1:56PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $82.15 to a high of $83.43. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $83.35 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LLY: 83.32 (+0.14)
Eli Lilly Set to Possibly Pullback After Yesterday's Rally of 1.15%
Comtex SmarTrend(R) - Wed Jul 27, 1:54PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $82.15 to a high of $83.43. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $83.35 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
LLY: 83.32 (+0.14)
A Waltz with Taltz - Dermatologists Report Early Adoption of Ixekizumab in Psoriasis
PR Newswire - Wed Jul 27, 9:28AM CDT
At approximately six weeks after launch of Eli Lilly's Taltz, one-third of surveyed dermatologists (n=99) report trialling the latest biologic. RealTime Dynamix(TM): Psoriasis is an independent report issued on a quarterly basis that provides highly granular brand insights on the psoriasis market.
LLY: 83.32 (+0.14)
Long-time Lilly CEO Lechleiter to retire in December
By TOM MURPHY - AP - Wed Jul 27, 7:43AM CDT
Eli Lilly Chairman and CEO John C. Lechleiter will retire in December after leading the drugmaker through a challenging period in which it lost U.S. patent protection for several top-selling products.
LLY: 83.32 (+0.14)
John C. Lechleiter to Retire as Lilly CEO; Board Elects David A. Ricks as Successor
PR Newswire - Wed Jul 27, 5:45AM CDT
Eli Lilly and Company (NYSE: LLY) today announced that John C. Lechleiter, Ph.D., chairman, president and chief executive officer, will retire as president and CEO and from the company effective December 31, 2016. Lechleiter will continue on Lilly's board of directors until May 31, 2017, serving as non-executive chairman, at which time he will leave the board. Lilly's board of directors unanimously elected David A. Ricks, currently senior vice president and president, Lilly Bio-Medicines, to assume the role of president and chief executive officer and to join the board on January 1, 2017, and to become chairman of the board on June 1, 2017.
LLY: 83.32 (+0.14)
Biogen (BIIB) Q2 Earnings: Will the Stock Disappoint?
Arpita Dutt - Zacks Investment Research - Fri Jul 15, 8:17AM CDT
Will Tecfidera scrips and sales recover enough to boost Biogen's (BIIB) performance in the second quarter?
BIIB: 330.11 (+28.28), GILD: 79.57 (-0.89), LLY: 83.32 (+0.14), NVS: 82.96 (-0.11)
J&J (JNJ) May Beat Q2 Earnings: Will the Stock Gain?
Arpita Dutt - Zacks Investment Research - Fri Jul 15, 7:52AM CDT
J&J (JNJ) has a pretty good track record and could beat estimates in the second quarter given the Zacks Rank #2 and +1.80% ESP.
JNJ: 124.85 (-0.55), GILD: 79.57 (-0.89), LLY: 83.32 (+0.14), NVS: 82.96 (-0.11)
Eli Lilly, Boehringer Collaborate for Metastatic Breast Cancer
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 9:25AM CDT
Eli Lilly (LLY) inked a clinical trial collaboration with Boehringer for the evaluation of abemaciclib-BI 836845 combination for metastatic breast cancer.
ABT: 45.07 (-0.22), JNJ: 124.85 (-0.55), INVA: 12.84 (-0.20), LLY: 83.32 (+0.14)
Lilly and Boehringer Ingelheim Announce Clinical Trial Collaboration in Metastatic Breast Cancer
PR Newswire - Wed Jul 13, 7:00AM CDT
Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced a new collaboration on a Phase 1b study that will evaluate the safety and tolerability of abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor, in combination with BI 836845, Boehringer Ingelheim's insulin-like growth factor (IGF)-1/IGF-2 ligand neutralizing antibody, in patients diagnosed with HR+, HER2- mBC. Based on the Phase 1b trial results, the collaboration has the potential to expand to Phase 2 trials in patients with HR+, HER2- mBC and other solid tumors. Enrollment is scheduled to begin in late 2016, and Boehringer Ingelheim will be the sponsor of the study program.
LLY: 83.32 (+0.14)
Testosterone Replacement Therapy (TRT) Market to Face Lean Patch until 2024 as it Inches Close to Patent Cliff, Says TMR
PR Newswire Europe - Tue Jul 12, 11:31AM CDT
ALBANY, New York, July 12, 2016 /PRNewswire/ --
AGN: 250.75 (-4.11), ENDP: 17.11 (+0.23), LLY: 83.32 (+0.14), ABBV: 66.78 (-0.16)
2016 INVESTIndiana Equity Conference Announces Corporate Presentation Lineup
BusinessWire - Tue Jul 12, 10:00AM CDT
INVESTIndiana, an equity conference that highlights the performance of Indiana public companies, today announced a presentation lineup that features Indiana's top health sciences companies as well as leaders in the banking, energy, high-tech and manufacturing sectors.
ESCA: 10.72 (+0.01), ININ: 56.96 (+5.31), ZBH: 130.59 (-0.47), GABC: 34.26 (-0.03), KBAL: 11.58 (+0.10), HBNC: 27.10 (-0.19), LLY: 83.32 (+0.14), LKFN: 50.80 (-0.43), SRCE: 33.56 (-0.15), ONB: 13.15 (+0.10), ECYT: 3.05 (-0.13), NI: 25.94 (+0.13), INBK: 22.21 (-0.67), BASI: 1.39 (+0.21), MFSF: 28.16 (-0.17)
Technical Report on Drug Manufacturers - Major Stocks - Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
PR Newswire - Mon Jul 11, 6:55AM CDT
On Friday, July 08, 2016, the NASDAQ Composite ended the trading session at 4,956.76, up 1.64%; the Dow Jones Industrial Average advanced 1.40%, to finish at 18,146.74; and the S&P 500 closed at 2,129.90, up 1.53%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Bristol-Myers Squibb Company (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Company (NYSE: LLY), and GlaxoSmithKline PLC (NYSE: GSK). Learn more about these stocks by accessing their free notes at:
AZN: 34.21 (+0.37), LLY: 83.32 (+0.14), GSK: 45.49 (+0.24), BMY: 75.05 (-1.14)
